Breast Surgery
RCT: An exercise program reduced upper limb disability one year after non-reconstructive breast cancer surgery.
18 Nov, 2021 | 08:39h | UTCCommentaries:
Exercise reduces upper limb disability after breast cancer surgery – BMJ / News Medical
Exercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery- HealthDay
Structured Exercise Improves Upper Limb Function After Breast Ca Surgery – Physician’s Weekly
Commentary on Twitter
Women who exercise shortly after having non-reconstructive breast cancer surgery appear to regain better shoulder and arm mobility and experience less pain than those who receive standard care, finds this study @jxbruce https://t.co/BhIKb8RRjV
— The BMJ (@bmj_latest) November 11, 2021
Review: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.
16 Nov, 2021 | 08:23h | UTCTreatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (free for a limited period)
Commentary on Twitter
A Review in @NatRevClinOncol describes the current and upcoming therapeutic landscape of triple-negative breast cancer. https://t.co/bcFTef01t1 pic.twitter.com/zFPyeeCnD5
— Nature Portfolio (@NaturePortfolio) November 15, 2021
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer.
11 Nov, 2021 | 08:32h | UTC
Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.
10 Nov, 2021 | 06:57h | UTCAntipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051
— PfOL (@psychopharmacol) September 12, 2021
RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.
27 Oct, 2021 | 01:28h | UTCEffect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)
Commentary on Twitter
Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer. IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors https://t.co/tw4ZrHn5wn pic.twitter.com/34ye3TR9MA
— JAMA Oncology (@JAMAOnc) October 25, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
21 Oct, 2021 | 09:48h | UTCPress release: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology
Case series: Assessment of silicone particle migration among women undergoing removal or revision of silicone breast implants in the Netherlands.
21 Sep, 2021 | 08:59h | UTCInvited commentary: Silicone Breast Implants and Disease—Many Questions Unanswered
Commentary on Twitter
In this case series including women w noncohesive or cohesive silicone gel breast implants, silicone leakage occurred in 98.8% of women, indicating silicone gel bleed, and in 86.6% of women, migration of silicone particles outside the capsule was detected. https://t.co/tyCpLw565Z
— JAMA Network Open (@JAMANetworkOpen) September 20, 2021
Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.
15 Sep, 2021 | 08:46h | UTC
Commentary on Twitter
For women with early-stage #BreastCancer, how does giving radiotherapy to part of the breast compare with giving #radiotherapy to the whole breast? The latest Cochrane Review from @CochraneBCancer brings together nine studies, which involved 15,187 women: https://t.co/fVuSrSDAZM pic.twitter.com/QOufZYSH5I
— Cochrane UK (@CochraneUK) September 3, 2021
Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.
14 Sep, 2021 | 08:44h | UTC
Commentary on Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— ASCO Publications (@ASCO_pubs) September 10, 2021
Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.
10 Sep, 2021 | 05:12h | UTCOriginal study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Commentary on Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.
25 Aug, 2021 | 08:59h | UTCRelated:
2 Case Series and Guidance| Lymphadenopathy in COVID-19 Vaccine Recipients
COVID-19 vaccine-linked adenopathies could mimic breast malignancies
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
Oncoplastic breast surgery: A guide to good practice.
19 Aug, 2021 | 08:40h | UTCOncoplastic breast surgery: A guide to good practice – European Journal of Surgical Oncology
Mammographic features are associated with cardiometabolic disease risk and mortality.
6 Aug, 2021 | 09:04h | UTC
ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.
30 Jul, 2021 | 11:51h | UTC
RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.
30 Jul, 2021 | 11:43h | UTC
Commentary on Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021
Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
30 Jul, 2021 | 11:49h | UTC
Systematic review: Breast Reconstruction After Mastectomy.
22 Jul, 2021 | 10:45h | UTCBreast Reconstruction After Mastectomy – Agency for Healthcare Research and Quality
Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.
14 Jul, 2021 | 11:07h | UTCNews release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre
RCT: Pectoral nerve blocks for breast augmentation surgery.
7 Jul, 2021 | 08:41h | UTCPectoral Nerve Blocks for Breast Augmentation Surgery: A Randomized, Double-blind, Dual-centered Controlled Trial – Anesthesiology (link to abstract – $ for full-text)
Commentary on Twitter
Better pain relief using PECS blocks in breast augmentation surgery. https://t.co/T0SIyR7zFn pic.twitter.com/4rrbj6eTFk
— Anesthesiology journal (@_Anesthesiology) June 29, 2021
M-A: Pregnancy After Breast Cancer – “These results provide reassuring evidence on the safety of conceiving in BC survivors”.
6 Jul, 2021 | 09:55h | UTCPregnancy After Breast Cancer: A Systematic Review and Meta-Analysis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history@OncoAlert #SurvOnc #bcsm
Link: https://t.co/lgKQDeB2VS pic.twitter.com/rTpFKsrpMc— Matteo Lambertini, MD PhD (@matteolambe) July 1, 2021
RCT: Similar outcomes with 5 vs. 2 years of zoledronate treatment following adjuvant chemotherapy in early breast cancer.
1 Jul, 2021 | 09:50h | UTCOriginal Study: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Population-based cohort study suggests increased survival after breast conservation surgery + radiotherapy compared to mastectomy with or without radiotherapy in women with breast cancer.
10 May, 2021 | 00:42h | UTC
Commentary on Twitter
Women receiving breast-conserving surgery for #breastcancer fare better than those who take away the whole breast says a new study taking into account comorbidities and socioeconomic background. Superior survival rates support less extensive surgery https://t.co/JEXasP56Di
— JAMA Surgery (@JAMASurgery) May 5, 2021
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
Systematic Review: PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
23 Apr, 2021 | 08:16h | UTCSummary: PARP inhibitors for locally advanced or metastatic breast cancer – Cochrane Library